GE HealthCare Acquires SOFIE Biosciences for $945 Million
GE HealthCare has agreed to acquire SOFIE Biosciences for $945 million in cash, expanding its radiopharmaceutical footprint and adding the Phase III pipeline PET radiotracer FAPI-74. The acquisition will integrate SOFIE Biosciences into GE HealthCare's Pharmaceutical Diagnostics segment and is expected to close in the first half of 2027, pending regulatory approvals. Following the announcement, GE HealthCare's share price increased.
Evercore ISI Adjusts GE Healthcare Technologies Price Target to $83 From $84, Maintains Outperform Rating
Evercore ISI has adjusted its price target for GE Healthcare Technologies (GEHC) from $84 to $83, while reiterating an "Outperform" rating on the stock. This adjustment comes alongside news that GE HealthCare plans to acquire Sofie Biosciences for $945 million to enhance its radiopharma business. The company also recently increased its quarterly dividend to $0.04 per share.
GE HealthCare is buying radiopharmaceutical maker Sofie Biosciences for $945 million
GE HealthCare has agreed to acquire Sofie Biosciences for $945 million to expand its pharmaceutical diagnostics footprint and add a late-stage cancer imaging tracer, FAPI-74, to its pipeline. Sofie Biosciences specializes in manufacturing and delivering radioactive tracer agents for PET imaging. The deal is expected to be revenue-accretive for GE HealthCare within its first complete year of ownership.
GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business
GE HealthCare is set to acquire Sofie Biosciences for $945 million in cash, aiming to bolster its radiopharma business and expand its capabilities in manufacturing and distributing PET imaging drugs. This acquisition grants GE HealthCare U.S. rights to FAPI-74, a promising experimental PET imaging agent for cancer detection, and strengthens its pharmaceutical diagnostics arm. The deal highlights a growing trend of consolidation in the radiopharmaceuticals market, driven by increasing use of radioactive drugs in cancer care.
GE HealthCare to acquire Sofie Biosciences for $945 million
GE HealthCare Technologies is set to acquire Sofie Biosciences for $945 million in cash. Sofie Biosciences specializes in manufacturing and delivering radioactive tracer agents for PET imaging. This acquisition will grant GE HealthCare U.S. rights to FAPI-74, a PET radiotracer in Phase III clinical trials for cancer detection, and is expected to be revenue-accretive within its first full year under GE HealthCare's ownership.
GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business
GE HealthCare is set to acquire privately held Sofie Biosciences for $945 million in cash, aiming to enhance its radiopharma business and expand its presence in the growing radiopharmaceuticals market. This acquisition will grant GE HealthCare US rights to FAPI-74, an experimental PET imaging agent for cancer detection, for which it already holds international rights. The deal underscores increasing M&A activity in the radiopharma industry as companies capitalize on the rising use of radioactive drugs in cancer care.
GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.
GE HealthCare announced its definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, for $945 million in cash. This acquisition will establish GE HealthCare's footprint in the "final mile" of U.S. PET radiopharmaceutical supply, expanding its capabilities in precision care and theranostics. The transaction, expected to close in the first half of 2027, will integrate SOFIE Biosciences' network of 15 CMO sites into GE HealthCare's PDx segment, aiming to improve patient access and supply reliability for novel radiopharmaceuticals.
Exclusive | GE HealthCare to Buy Sofie for Nearly $1 Billion to Grow Medical-Imaging Business
GE HealthCare announced its plan to acquire Sofie, a manufacturer of radioactive substances for medical imaging, for $945 million in cash. This acquisition expands GE HealthCare's presence in the growing radiopharmaceuticals market. Radiopharmaceuticals are used in diagnosing and treating conditions like cancer, heart disease, and Alzheimer's.
15 U.S. sites make medicines used in PET scans. GE HealthCare has agreed to buy SOFIE Biosciences.
GE HealthCare has announced a definitive agreement to acquire SOFIE Biosciences, a U.S.-based Contract Manufacturing Organization (CMO) for PET radiopharmaceuticals, for $945 million in cash. This acquisition will expand GE HealthCare's footprint in the U.S. radiopharmaceutical industry, adding 15 CMO sites and enhancing patient access to novel radiopharmaceuticals. The deal also includes U.S. rights to FAPI-74, a Phase III PET radiotracer with significant potential for cancer imaging, and is expected to be accretive to GE HealthCare's revenue growth and earnings in the first year of ownership.
GE HealthCare said to buy Sofie Boisciences for nearly $1B
The article reports that GE HealthCare is rumored to be acquiring Sofie Biosciences for close to $1 billion. This acquisition is significant in the healthcare and life sciences sectors.
GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.
GE HealthCare announced its definitive agreement to acquire SOFIE Biosciences for $945 million in cash, aiming to strengthen its footprint in the U.S. radiopharmaceutical industry and ensure reliable patient access to PET radiopharmaceuticals. The acquisition will integrate SOFIE Biosciences' network of 15 CMO sites and 21 cyclotrons into GE HealthCare's Pharmaceutical Diagnostics segment, enabling participation in high-growth areas and providing solutions across the theranostics pathway. This deal also grants GE HealthCare U.S. rights to FAPI-74, a promising Phase III PET radiotracer for pan-cancer imaging, and is expected to be accretive to revenue growth and earnings in its first full year.
ESAB Q2 2026 Earnings Call: Complete Transcript
ESAB Corporation reported record total sales of $766 million in Q2 2026, a 13% year-over-year increase, with 2.5% organic growth driven by automation and equipment. The acquisition of Edify was completed ahead of schedule, contributing to future organic growth and margin expansion. The company raised its full-year 2026 outlook, expecting total core sales of $3.0 to $3.1 billion and adjusted EBITDA of $615 to $625 million, while acknowledging transitory price-cost neutrality impacts and geopolitical headwinds in the Middle East.
GE HealthCare stock pre-market at EUR 57.22: minus 0.10 percent
GE HealthCare's stock saw a slight pre-market dip of 0.10 percent, trading at EUR 57.22. The company recently announced a quarterly cash dividend of $0.04 per common share, marking a 14 percent increase from the previous quarter, payable on November 13, 2026. Additionally, Pascal Desroches, CFO of AT&T, has been appointed to GE HealthCare's board of directors, effective January 4, 2027.
GE HealthCare stock heads toward a higher quarterly dividend
GE HealthCare (GEHC) is moving towards a higher quarterly dividend of USD 0.04 per share, payable on November 13, 2026, following a 14 percent increase announced by its board. This increase comes as the company reports mixed Q2 2026 results with growth in Advanced Imaging and Pharmaceutical Diagnostics, offset by a decline in Patient Care Solutions. Analysts maintain a "Moderate Buy" consensus with price targets significantly above the current stock price, despite the stock trading below its yearly high.
RBC Capital Reaffirms Their Hold Rating on W. P. Carey Inc. (WPC)
RBC Capital has reaffirmed its Hold rating on W. P. Carey Inc. (WPC) with a price target of $67.00. This rating comes despite Jefferies initiating coverage with a Buy rating and Scotiabank also issuing a Hold. The company's latest financial report showed quarterly revenue of $342.22 million and a net profit of $185.93 million.
RBC Capital Sticks to Their Buy Rating for GE Healthcare Technologies Inc (GEHC)
RBC Capital analyst Kendall Au maintained a Buy rating on GE Healthcare Technologies Inc (GEHC) with a price target of $80.00, representing a 25.04% upside from its previous closing price of $63.98. Needham also initiated coverage with a Buy rating and a $93.00 price target. The company reported a quarterly revenue of $5.3 billion and a net profit of $573 million in its latest earnings report.
Boston Scientific (BSX) Receives a Buy from RBC Capital
RBC Capital analyst Kendall Au maintained a Buy rating on Boston Scientific (BSX) with a $70.00 price target. This aligns with a general "Strong Buy" consensus among analysts, predicting a 35.51% upside. The company recently reported strong quarterly revenues of $5.44 billion and a net profit of $907 million, alongside positive insider sentiment with increased insider stock purchases.
RBC Capital Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)
RBC Capital analyst Kendall Au reiterated a Buy rating on Zimmer Biomet Holdings (ZBH) with a price target of $110.00. This affirmation follows the company's Q2 earnings report, which showed increased revenue and net profit compared to the previous year. Zimmer Biomet Holdings currently holds a Moderate Buy consensus among analysts, with an average price target of $106.07.
RBC Capital Maintains GE HealthCare Technologies(GEHC.US) With Buy Rating, Maintains Target Price $80
RBC Capital has reaffirmed its "Buy" rating on GE HealthCare Technologies (GEHC.US), keeping its target price at $80. This indicates the firm's continued positive outlook on the company's stock performance.
GE HealthCare raises dividend to USD 0.04 per GE HealthCare stock
GE HealthCare has declared a third-quarter dividend of USD 0.04 per share, a 14% increase from the previous quarter, signaling a new capital-return angle for the company. This dividend hike comes as the company reports a 5.70% rise in revenue to USD 5.30 billion in Q2 2026 and robust organic order growth. Analysts at BTIG have reiterated a Buy rating and raised their price target for GE HealthCare stock to USD 79.00.
STERIS (STE) Dividend Yield 2026, Date & History $STE
This article provides a detailed overview of STERIS (STE) dividend information for 2026, including its dividend yield, annual dividend, and payment history. STERIS pays quarterly dividends, has increased its dividend for 20 consecutive years, and maintains a healthy payout ratio. The report also compares STERIS's dividend performance against healthcare and NYSE averages and addresses frequently asked questions about its dividend.
CJR Model's $180M savings pave way for nationwide expansion
Medicare's Comprehensive Joint Replacement (CJR) Model saved $180 million in its final three years without compromising care quality, according to a new CMS report. This success paves the way for a nationwide expansion of bundled payment models, with a successor model, CJR Expanded (CJR-X), slated to begin in 2028. The savings primarily stemmed from reductions in institutional post-acute care spending, particularly in inpatient rehabilitation facilities.
GE HealthCare stock after-hours at EUR 57.15: minus 1.40 percent versus Lang & Schwarz prior close
GE HealthCare stock traded at EUR 57.15 after-hours, a 1.40 percent drop from its prior close on Lang & Schwarz. The company announced the appointment of Pascal Desroches to its Board of Directors and declared a third-quarter cash dividend of USD 0.04 per common share, representing a 14 percent increase.
Medtronic reveals cardiac mapping and ablation software clearances
Medtronic announced it has received regulatory clearances for new cardiac mapping and ablation software in both the U.S. and Europe. The clearances are for its Affera Prism-2 Mapping Software and a CE mark for the PulseSelect ProxBox Adapter with Proximity Indicator software, aiming to enhance the company's position in the competitive pulsed field ablation market. These software advancements are designed to provide physicians with better visualization and real-time feedback during cardiac ablation procedures.
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Nektar Therapeutics (NKTR) and Stryker (SYK)
This article provides an overview of analyst ratings for three healthcare companies: DocGo (DCGO), Nektar Therapeutics (NKTR), and Stryker (SYK). DocGo received a Hold rating from BTIG, with a Moderate Buy consensus. Nektar Therapeutics maintained a Buy rating from BTIG and a Strong Buy consensus, while Stryker received a Buy rating from Stifel Nicolaus and a Strong Buy consensus.
Viatris Inc. (VTRS) stock price, news, quote and history
This article provides a comprehensive overview of Viatris Inc. (VTRS) stock, including its current price, historical data, financial performance, and analyst insights. It details the company's operations as a healthcare provider specializing in prescription brand drugs, generic drugs, and biosimilars across various global markets. Key financial metrics, recent news, and performance comparisons against the S&P 500 are also included.
GE HealthCare (GEHC) Upgraded to Buy: Here's Why
GE HealthCare (GEHC) has received a Zacks Rank #2 (Buy) upgrade, driven by an upward trend in earnings estimates. This positive outlook on future earnings is a significant indicator for stock price movement, as institutional investors often adjust their valuations based on such revisions. The upgrade suggests an improvement in GE HealthCare's underlying business and positions the stock among the top 20% of Zacks-covered stocks.
GE HealthCare stock after-hours at EUR 58.07: minus 0.90 percent versus prior close
GE HealthCare's stock traded after-hours at EUR 58.07, showing a 0.90 percent decrease compared to its previous close. This price movement followed announcements regarding AsiaMedic's implementation of GE HealthCare's MR31 MRI platform and the appointment of Pascal Desroches to the board of directors, effective January 4, 2027.
GE HealthCare (GEHC) Upgraded to Buy: Here's Why
GE HealthCare (GEHC) has been upgraded to a Zacks Rank #2 (Buy), driven by an upward trend in earnings estimates. The Zacks rating system highlights the strong correlation between revisions in earnings estimates and near-term stock price movements, making it a useful tool for investors. The positive outlook for GE HealthCare's earnings suggests an improvement in its underlying business, which could lead to increased buying pressure and a higher stock price.
GE HealthCare hires new global chief AI officer
GE HealthCare has appointed Rodolphe Katra, former global chief AI officer at Medtronic, as its new global chief AI officer. Katra will report to CTO Taha Kass-Hout and focus on integrating devices, software, and data to enhance AI strategies. This appointment follows the departure of GE HealthCare's first chief AI officer, Parminder Bhatia, and aims to further cement the company's leadership in AI-enabled medical devices, of which it currently has 134 FDA-authorized.
Licensable picture: GE Healthcare brand logo
The article describes a licensable image of the GE HealthCare Technologies Inc. logo on an office building in Munich, Germany. GE HealthCare, a medical technology company, specializes in diagnostic imaging, digital solutions, patient monitoring, and pharmaceutical diagnostics. The image is provided by DPA / Picture Alliance via Reuters Connect.
GE HealthCare stock pre-market at EUR 58.59: minus 0.02 percent
GE HealthCare's stock was trading at EUR 58.59 pre-market, marking a 0.02 percent decrease from its previous close. The company also announced a quarterly cash dividend of USD 0.04 per common share, payable on November 13, 2026. Additionally, Pascal Desroches, AT&T's CFO, was appointed to GE HealthCare's board of directors, effective January 4, 2027.
Can ResMed (ASX:RMD) Hit Its Outlook After Retiring the Astral Ventilator?
ResMed (ASX:RMD) has reaffirmed its full-year outlook despite facing a revenue headwind from a field safety action related to its Astral ventilator, which the company plans to retire. The medical device manufacturer expects to absorb the impact due to the Astral platform being a relatively small part of its overall revenue compared to its core sleep apnoea business. Analysts are closely watching gross margin progress and operating expense discipline, alongside broader market sentiment, to assess the stock's future performance.
How to Play First United Stock After Its Dividend Increase
First United (FUNC) recently increased its quarterly dividend by nearly 8%, signaling strong financial health and management confidence. The Maryland-based bank holding company reported strong Q2 2026 earnings, including a revenue beat and expanded net interest margin, reinforcing its investment appeal for income-focused investors. Analysts currently rate FUNC a "Moderate Buy" with an average price target implying a 13% upside.
Licensable picture: GE Healthcare brand logo
The article features a licensable picture of the GE HealthCare Technologies Inc. brand logo displayed on an office building in Munich, Germany. GE HealthCare is a medical technology company specializing in diagnostic imaging, digital solutions, patient monitoring, and pharmaceutical diagnostics. The image is provided by DPA / PICTURE ALLIANCE through Reuters Connect.
Here's Why You Should Add GEHC Stock to Your Portfolio Right Now
GE HealthCare Technologies (GEHC) is positioned for growth due to strong order momentum, a record backlog, and advancements in its Pharmaceutical Diagnostics business and AI-enabled innovations. Despite potential headwinds from inflation and challenges in the Chinese market, the company's strategic shift towards integrated customer relationships and its new AI products are expected to drive long-term revenue and margin expansion. GEHC is currently a Zacks Rank #2 (Buy) stock, with positive estimate revisions for 2026.
GE HealthCare Technologies Inc. (GEHC) Latest Stock News & Headlines
This article provides a compilation of recent news and headlines concerning GE HealthCare Technologies Inc. (GEHC). It covers various topics including dividend announcements, stock performance analysis, market trends in remote cardiac monitoring, and the appointment of new board members. The collected headlines also discuss GEHC's strategic moves like the launch of its CareIntellect AI tool and potential acquisitions.
Here's Why You Should Add GEHC Stock to Your Portfolio Right Now
GE HealthCare Technologies (GEHC) is positioned for future growth due to a record backlog, strong order momentum, and advancements in its Pharmaceutical Diagnostics business and AI-enabled innovations. Despite these positives, inflationary pressures and higher input costs pose risks to profitability, and China's market remains a structural headwind for revenue. The company maintains a Zacks Rank #2 (Buy) and expects continued strong performance, driven by its multi-period revenue pipeline and focus on integrated customer relationships.
Nurses dissatisfied with AI implementation, feel 'watched' by AI
A new survey by Black Book Research indicates that many nurses are dissatisfied with AI implementation in hospitals, with nearly half expressing dissatisfaction and 65% feeling surveilled by AI systems. This dissatisfaction stems from increased workloads, extra documentation, and a perceived lack of understanding from leadership regarding AI's impact on nursing workflows. The survey suggests that these issues could hinder AI adoption in healthcare, as many nurses are considering less AI-intensive roles.
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus
CapsoVision has announced that the FDA has granted 510(k) clearance for AI Highlights, an AI-powered module for its CapsoCam Plus small bowel capsule endoscopy system. This new feature aims to enhance the efficiency and accuracy of reviewing small bowel capsule endoscopy studies by automatically identifying and flagging regions of interest. The company expects the AI Highlights module to be available in the United States in early 2027.
GE HealthCare to explore applying generative AI to radiation therapy workflows
GE HealthCare is partnering with Mass General Brigham to integrate generative AI into radiation therapy workflows, aiming to help care teams access and synthesize patient-specific information more efficiently. This collaboration seeks to personalize patient care by combining structured healthcare data with unstructured information like clinical notes and images, allowing clinicians to query data and make better-informed decisions. The initiative addresses the complexity and fragmentation of current radiation therapy pathways and aligns with a broader industry trend of incorporating generative AI into medical devices.
GE HealthCare stock gets Needham's USD 93.00 target
Needham has set a $93.00 price target for GE HealthCare (GEHC) with a Buy rating, citing expected faster growth in advanced imaging systems and stronger earnings. The stock, last trading at $66.63, is below its 52-week high but above its low, despite strong Q2 2026 revenue of $5.295 billion and adjusted EPS of $1.13. Analyst consensus shows a "Moderate Buy" with an average target of $78.39, indicating a mixed but generally constructive outlook for the company.
Healthcare Equipment and Supplies Stocks Q2 Highlights: GE HealthCare (NASDAQ:GEHC)
This article reviews the Q2 performance of several healthcare equipment and supplies stocks, highlighting GE HealthCare (GEHC), Baxter (BAX), LeMaitre (LMAT), STERIS (STE), and Lantheus (LNTH). It details their revenue performance against analyst expectations and stock price movements, noting GE HealthCare's satisfactory quarter with increased orders, Baxter's strong revenue beat, LeMaitre's disappointing results and guidance, STERIS's mixed quarter, and Lantheus's impressive revenue and EPS beat. The sector as a whole saw a decline in share prices despite revenues generally beating estimates.
GE HealthCare Technologies (GEHC) Stock Price, News & Analysis
This article provides an overview of GE HealthCare Technologies (GEHC), detailing its stock performance, recent news, SEC filings, financial highlights, and business segments. GEHC is a global healthcare solutions provider focusing on medical technology, pharmaceutical diagnostics, and AI-enabled solutions, operating through four primary businesses: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. The company reported $20.6 billion in revenue for FY2025 and is recognized for its innovation and collaborations within the healthcare industry.
Viatris Inc. (VTRS) stock price, news, quote and history
Viatris Inc. (VTRS) is a healthcare company that operates globally, manufacturing prescription brand drugs, generic drugs, complex generics, and biosimilars across various therapeutic areas. The article provides detailed financial information including its stock performance, market capitalization, earnings trends, analyst ratings, and a company overview. Viatris reported a Q2 FY26 revenue of $3.76 billion and an EPS (TTM) of -0.38, with analysts estimating a 1-year target price of $19.40.
Westinghouse Air Brake Technologies Corporation (WAB) Stock Price, News, Quote & History
This article provides detailed financial information, news, and historical data for Westinghouse Air Brake Technologies Corporation (WAB), a company specializing in locomotives, equipment, systems, and services for the freight rail and passenger transit industries. It covers stock performance, key financial metrics, earnings trends, analyst insights, and company overview.
Oklo’s Isotope Test Reactor achieves criticality
Oklo's Groves Isotope Test Reactor has achieved criticality, becoming the fifth Department of Energy-authorized reactor to do so. This significant milestone was reached in Lockhart, Texas, in less than a year from a greenfield site, setting a new benchmark for advanced nuclear deployment. The project is part of Oklo Isotopes' broader strategy to build domestic isotope production facilities for various applications, including health care and national security.
Dividend Roundup: AT&T, Delta Air Lines, Philip Morris, Target, and more
This week's dividend roundup highlights increased payouts from GE HealthCare Technologies and T-Mobile US, along with declarations from AT&T and Delta Air Lines. The article also previews upcoming dividend declarations from major industry players like Philip Morris. This information is crucial for investors tracking dividend income.
GE HealthCare stock heads into the open after a flat market session
GE HealthCare stock is heading into the open after a flat market session on September 24, 2026. The S&P 500 closed slightly down, while the Nasdaq Composite saw a small gain. Investors will be observing how GE HealthCare shares perform today, September 25, 2026, considering the previous day's market context.
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
This article compares Intuitive Surgical (ISRG) and Stryker (SYK), two major players in the MedTech sector, evaluating which is the better investment. While Stryker offers diversified MedTech exposure and recovering capital-product momentum, Intuitive Surgical presents a more focused growth story with stronger operational momentum and a growing digital ecosystem. The article concludes that Intuitive Surgical is currently the more attractive bet due to its robotics leadership, recurring revenues, and expanding clinical applications, despite trading at a higher premium.
